Safety risks in intravenous chemotherapy do not concentrate within any single operational stage but instead accumulate and transmit in a chain-like pattern at inter-stage junctions, according to a qualitative descriptive study conducted at a tertiary hospital in Suzhou, China. The research evaluated safety vulnerabilities across the clinical medication trajectory by gathering direct evidence from healthcare professionals and patients rather than examining clinical tasks in isolation.
The investigation utilized the World Health Organization medication-use process alongside Hazard Analysis and Critical Control Points principles as an analytical framework to map how hazards emerge and propagate. Semi-structured interviews were conducted between April and September 2025 at a tertiary hospital in Suzhou, China. Researchers analyzed the resulting interview data using directed content analysis in NVivo version 15.0 and structured their reporting according to the Consolidated Criteria for Reporting Qualitative Research guidelines.
The study engaged a purposive, multi-stakeholder sample consisting of 13 oncology nurses, seven physicians, three pharmacists, and 11 patients. By synthesizing insights across these distinct clinical roles and care recipients, the research team identified safety vulnerabilities that extended beyond the observational scope of single-profession or stage-confined assessments.
Across the four core chemotherapy phases of prescribing, compounding, administration, and monitoring, the analysis classified four primary themes and 13 subthemes. These findings exposed stage-specific vulnerabilities centered around information integrity, process verification, implementation consistency, and continuity of care across the treatment continuum.
The study identified three cross-cutting mechanisms underpinning risk transmission between clinical junctions: information discontinuity, where incomplete patient details pass unverified across hospital stages and external healthcare institutions; accountability gaps, where risks lack clear ownership during care handovers and following patient discharge; and procedural-implementation deviation, wherein safety checks remain documented in form but are weakened in actual protective function under real-world operational constraints.
Based on these observations, the authors concluded that hospital safety management should extend beyond measuring compliance within isolated stages to actively safeguarding inter-stage connections by verifying patient records at every transition, clarifying professional responsibilities across care environments, and assessing whether safety checks fulfill their intended verification purpose. Because the investigation was conducted at a single tertiary center, the authors noted that their conceptual risk-transmission framework requires further validation through multicentre and quantitative studies.
Prior evaluations of intravenous chemotherapy administration have largely concentrated on discrete stages or individual professional silos, leaving the systemic mechanisms of risk accumulation across interconnected care transitions insufficiently characterised.
Subject of Research: Intravenous chemotherapy administration safety and inter-stage risk transmission
Article Title: Key risk factors in intravenous chemotherapy administration safety: a multi-stakeholder qualitative study
Article References: Liu, D., Wang, Q., Wang, X., Yuan, Y., Wang, F., Xu, L., & Tong, Y. (2026). Key Risk Factors in Intravenous Chemotherapy Administration Safety: A Multi-Stakeholder Qualitative Study. Frontiers in Health Services, 6, 1971730. https://doi.org/10.3389/frhs.2026.1971730
Image Credits: AI Generated
DOI: 10.3389/frhs.2026.1971730
Keywords: intravenous chemotherapy, chemotherapy administration, medication safety, patient safety, qualitative research, Hazard Analysis and Critical Control Points, HACCP, WHO medication-use process, inter-stage risk transmission, oncology nursing, clinical handovers, directed content analysis, COREQ, information discontinuity, accountability gaps, procedural deviation, chemotherapy compounding, treatment monitoring
News Source: Nathaniel Bowman. (November 11, 2026). Intravenous chemotherapy risks accumulate at inter-stage transitions, qualitative study finds. Scienmag.



